New results reveal 90 percent patients with transfusion-dependent
β-thalassemia no longer required monthly blood transfusions years after
receiving gene therapy. The Phase III trial enrolled 22 patients, 20 of which
(91 percent), including six of the seven patients (86 percent) who were younger
than 12 years of age, achieved transfusion independence.

“It is impressive that so many patients in the study, including
the youngest patients, acquired transfusion independence that was durable,”
stated study co-author Dr Jennifer Schneiderman, from the Center for Cancer and
Blood Disorders at Ann & Robert H. Lurie Children’s Hospital of Chicago and
Associate Professor of Pediatrics at Northwestern University Feinberg School of
Medicine, both US.

“At Lurie Children’s, we have participated in these gene therapy
trials from the earliest stages and have been enrolling patients for close to a
decade. The current study represents the next step in moving this intervention
into clinical practice, which will increase access to a potential cure for
patients with transfusion-dependent thalassemia.”

β-thalassemia patients do not produce sufficient functional
haemoglobin in their red blood cells, disrupting oxygen transfer within the
body. Those with the most severe type of the disease require red blood cell
transfusions every month for survival.

Frequent transfusions, however, can cause serious complications
due to iron overload and infections, especially if the patient’s spleen has
been removed.

Haematopoietic stem cell transplantation from someone who makes
functional haemoglobin can be a potentially curative treatment for
β-thalassemia, but it requires a well-matched donor, which can be difficult to
find. It also poses a risk for graft versus host disease.

The trial evaluated an ex vivo gene therapy, Betibeglogene
autotemcel (beti-cel), containing autologous CD34+ haematopoietic stem cells
and progenitor cells transduced with the BB305 lentiviral vector encoding the
functional β-globin (βA-T87Q) gene. Before the modified cells are infused to
the patients, they are treated with chemotherapy.

Patients typically reached transfusion-free status about one month
after the autologous stem cell transplantation. Patients reported in the paper
had been monitored for a range of 13 months to four years after receiving their
new cells.


Addnoral Network


Health ,

Welcome to ADDNORAL Network

Discover more from ANINEWS24

Subscribe to get the latest posts sent to your email.


Leave a Reply